FDA OKs Bristol Myers Squibb’s LAG-3 drug, approving first new class of checkpoint inhibitor in 8 years

For the first time in nearly a decade, the FDA has approved a new type of checkpoint inhibitor to treat certain patients with cancer. …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA OKs Bris­tol My­ers Squibb’s LAG-3 drug, ap­prov­ing first new class of check­point in­hibitor in 8 years